With Singulair Gone, It’s Test Time For Merck’s Post-LOE Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
With Singulair’s loss of exclusivity on Aug. 3, Merck’s bets on growth of its existing franchises and late-stage pipeline have come under scrutiny. Next up: Tredaptive Phase III data in early 2013.